There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Tenet Healthcare (THC – Research Report) and Frequency Therapeutics (FREQ – Research Report) with bullish sentiments.
Biogen (BIIB)
In a report issued on January 19, Brian Skorney from Robert W. Baird maintained a Buy rating on Biogen, with a price target of $340.00. The company’s shares closed last Friday at $285.77.
According to TipRanks.com, Skorney has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $316.50, representing a 12.1% upside. In a report issued on January 4, Jefferies also maintained a Buy rating on the stock with a $350.00 price target.
See the top stocks recommended by analysts >>
Tenet Healthcare (THC)
Mizuho Securities analyst Ann Hynes maintained a Buy rating on Tenet Healthcare on January 19 and set a price target of $60.00. The company’s shares closed last Friday at $51.54.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of
Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $64.07.
Frequency Therapeutics (FREQ)
In a report issued on January 20, Jack Allen from Robert W. Baird maintained a Buy rating on Frequency Therapeutics, with a price target of $10.00. The company’s shares closed last Friday at $4.75.
According to TipRanks.com, Allen has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Frequency Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIIB:
- Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
- Eisai submits marketing authorization application for lecanemab in Japan
- FDA Commissioner defends FDA’s approval of Biogen’s Aduhelm, WSJ reports
- Eisai submits MAA for lecanemab to EMA
- FDA review suggests high amenability for a full leca approval, says RBC Capital
